Sclerosis Center At Charles University News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Autologous hematopoietic stem cell transplantation is linked to significantly lower relapse rates than fingolimod in patients with relapsing-remitting multiple sclerosis. But adverse events are common.

Czech republicNew south walesTomas kalincikKubala havrdovEva kubala havrdovNeuroimmunology serviceResearch gapUniversity of melbourneSclerosis center at charles universityResearch in multiple sclerosisEuropean committee for treatmentEuropean committeeMultiple sclerosisMedscape medical newsRoyal melbourne hospitalMultiple sclerosis center